國家衛生研究院 NHRI:Item 3990099045/12541
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855450      Online Users : 1120
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12541


    Title: Impacts of intralipid on nanodrug abraxane therapy and on the innate immune system
    Authors: Chen, YJ;Tsai, CY;Cheng, YM;Nieh, SW;Yeh, TK;Chen, CP;Wang, MH;Chou, LH;Chiu, TY;Liu, L;Ho, C;Chen, CT;Liu, TW
    Contributors: National Institute of Cancer Research;Institute of Biotechnology and Pharmaceutical Research
    Abstract: A major obstacle to nanodrugs-mediated cancer therapy is their rapid uptake by the reticuloendothelial system that decreases the systemic exposure of the nanodrugs to tumors and also increases toxicities. Intralipid has been shown to reduce nano-oxaliplatin-mediated toxicity while improving bioavailability. Here, we have found that Intralipid reduces the cytotoxicity of paclitaxel for human monocytic cells, but not for breast, lung, or pancreatic cancer cells. Intralipid also promotes the polarization of macrophages to the anti-cancer M1-like phenotype. Using a xenograft breast cancer mouse model, we have found that Intralipid pre-treatment significantly increases the amount of paclitaxel reaching the tumor and promotes tumor apoptosis. The combination of Intralipid with half the standard clinical dose of Abraxane reduces the tumor growth rate as effectively as the standard clinical dose. Our findings suggest that pre-treatment of Intralipid has the potential to be a powerful agent to enhance the tumor cytotoxic effects of Abraxane and to reduce its off-target toxicities.
    Date: 2020-02-18
    Relation: Scientific Reports. 2020 Feb 18;10:Article number 2838.
    Link to: http://dx.doi.org/10.1038/s41598-020-59813-7
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2045-2322&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000560400000006
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079611041
    Appears in Collections:[Tsang-Wu Liu] Periodical Articles
    [Chiung-Tong Chen] Periodical Articles
    [Teng-Kuang Yeh] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB32071352.pdf2183KbAdobe PDF301View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback